Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.07%
1,101.37
-0.81
-0.07%
—1,102.181,096.241,103.051,090.35——
SIXC
Communications
SIXC
Communications
SIXC
-0.47%
613.35
-2.89
-0.47%
—616.24616.24617.68609.10——
SIXE
Energy
SIXE
Energy
SIXE
+0.77%
1,198.83
+9.11
+0.77%
—1,189.721,194.741,202.791,188.58——
SIXI
Industrials
SIXI
Industrials
SIXI
+1.75%
1,755.95
+30.26
+1.75%
—1,725.691,730.021,762.991,730.02——
SIXM
Financials
SIXM
Financials
SIXM
-0.79%
638.51
-5.11
-0.79%
—643.62643.13643.17632.59——
SIXR
Staples
SIXR
Staples
SIXR
+1.65%
843.52
+13.73
+1.65%
—829.79832.32845.25832.32——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.19%
215.95
+2.55
+1.19%
—213.40213.40216.07213.40——
SIXT
Technology
SIXT
Technology
SIXT
-1.48%
3,138.91
-47.01
-1.48%
—3,185.923,160.893,178.723,102.60——
SIXU
Utilities
SIXU
Utilities
SIXU
+2.80%
934.37
+25.43
+2.80%
—908.94912.57934.91912.57——
SIXV
Health care
SIXV
Health care
SIXV
-0.10%
1,477.43
-1.53
-0.10%
—1,478.961,478.171,482.911,466.65——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-1.05%
2,380.19
-25.17
-1.05%
—2,405.362,390.342,402.532,359.18——
SRPT:NASDAQ
Sarepta Therapeutics Inc
$20.42
-1.07%
(-0.22) 1D
$20.42
0.00% (0.00)
After hours
Closed: Apr 23, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SRPT...
Open
$20.40
High
$20.54
Low
$18.38
Mkt. cap
2.14B
Avg. vol.
3.11M
Volume
0.00
52-wk high
$64.80
52-wk low
$10.42
EPS
-$7.13
Beta
0.29
Shares outstanding
104.99M
No. of employees
835
News stories
From sources across the web
Profile
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs. Wikipedia
About Sarepta Therapeutics Inc
CEODouglas S. Ingram
Employees835
Founded1980
Headquarters-
SectorBiotechnology
Websitesarepta.com
Last report
Feb 25, 2026
Fiscal Period
Q4 2025
Normalized EPS / Estimate
-3.58/ (-0.77 est.)USD
-365.29%miss
Revenue / Estimate
442.93M/ (390.95M est.)USD
+13.30%beat
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
744.86M
611.09M
399.36M
442.93M
Cost of goods sold
911.01M
356.95M
369.66M
724.04M
Cost of revenue
911.01M
356.95M
369.66M
724.04M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
133.63M
137.90M
91.89M
128.30M
Operating expense
134.23M
138.56M
92.57M
128.97M
Total operating expenses
1.05B
495.51M
462.24M
853.02M
Operating income
-300.39M
115.58M
-62.88M
-410.08M
Other non operating income
-329.00K
-573.00K
-702.00K
-338.00K
EBT including unusual items
-383.52M
153.64M
-194.05M
-278.30M
EBT excluding unusual items
-295.03M
115.03M
-63.90M
-423.20M
Income tax expense
63.99M
-43.25M
-14.10M
4.55M
Effective tax rate
-16.68%
-28.15%
7.27%
-1.64%
Other operating expenses
-
-
-
-
Net income
-447.51M
196.89M
-179.95M
-282.85M
Net profit margin
-60.08%
32.22%
-45.06%
-63.86%
Earnings per share
-3.42
2.02
-0.13
-3.58
Interest and investment income
10.19M
5.25M
7.25M
8.07M
Interest expense
-4.50M
-5.23M
-7.56M
-20.84M
Net interest expenses
5.69M
26.00K
-316.00K
-12.77M
Depreciation and amortization charges
-
-
-
-
EBITDA
-290.41M
126.42M
-44.43M
-404.83M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer